Anatomage Inc. Announces the Winners of the 2025 National Anatomage Tournament
Every year, thousands of students across the country participate in fast-paced, interactive competitions using the Anatomage Table, a state-of-the-art medical education platform featuring digitized real human cadavers. At their regional and state tournaments, teams of 3 to 4 students maneuvered 3D bodies to locate and identify anatomical structures, vying for a top 4 finish to qualify for the National Anatomage Tournament.
This year's tournament brought together the very best high school teams, with over 8,000 students from more than 2,200 teams participating in 44 tournaments across the country. The result: 80 teams who were able to demonstrate their academic excellence and become eligible for a chance to become National Anatomy Champions.
At the national tournament, each team competed in a 40-question preliminary round that tested their ability to identify anatomical structures using the Anatomage Table's lifelike digital cadavers. Scores from this round determined placement in the Top 32 bracket, where the format shifted to high-stakes, head-to-head matchups in a single-elimination style. The final eight teams emerged to compete on the main stage during the live-streamed Championship, battling through three increasingly difficult rounds of anatomy and physiology challenges in pursuit of the national title.
The winners:
1st place: Arcadia High School, No Apaches Down from Arcadia, CA
2nd place: Francis Tuttle Technology Center, Peters' Puppies from Oklahoma City, OK
3rd place: Francis Tuttle Technology Center, The Team Formerly Known As Ketchup from Oklahoma City, OK
4th place: Boyd J Michael III Technical High School, McDreamy Teamy from Hagerstown, MD
Participation in the National Anatomage Tournament not only showcases a student's mastery of anatomy and physiology, but also serves as a powerful testament to their academic rigor and commitment to excellence. Competing in this premier event demonstrates superior critical thinking, problem-solving, and collaborative skills. Their journey reflects the core mission of the Anatomage Tournament: to celebrate student achievement, encourage collaboration, and inspire a passion for medical education through advanced visualization technology and dynamic competition.
To learn more about the tournament and how to qualify for next year's competition, visit the Anatomage Tournament website.
About Anatomage
Anatomage is a market leader in medical imaging and education technology, transforming traditional learning through continuous innovation. With an ecosystem of medical imaging software and hardware, the company delivers world-class anatomy and physiology content at the highest level of accuracy. Anatomage is committed to enhancing its technologies to transform standard anatomy learning, medical diagnosis, treatment planning, as well as revolutionize science education.
Media Contact:Dr. Jack ChoiCEO, Anatomage Inc.Phone: 1-408-885-1474Email: info@anatomage.comwww.anatomage.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/anatomage-inc-announces-the-winners-of-the-2025-national-anatomage-tournament-302477984.html
SOURCE Anatomage Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
$7.80 Billion by 2030: Why Single-Use Surgical Instruments Are Reshaping Global Surgery
DELRAY BEACH, Fla., July 3, 2025 /PRNewswire/ -- What's fueling the shift from sterilization to scalability? The global single-use surgical instruments market, valued at US$5.60 billion in 2024, stood at US$5.92 billion in 2025 and is projected to advance at a resilient CAGR of 5.7% from 2025 to 2030, culminating in a forecasted valuation of US$7.80 billion by the end of the period. This growth is being driven by the rise of minimally invasive, short-stay, and outpatient surgeries—procedures that demand efficiency, sterility, and speed. Disposable tools are no longer just convenient—they are mission-critical assets for modern surgical care. Download PDF Brochure: Why are single-use surgical instruments becoming a new clinical benchmark? In high-risk surgeries such as general, ophthalmic, dental, and cardiovascular procedures, hospitals are under pressure to minimize infection, reduce turnaround time, and ensure tool readiness. Single-use instruments meet these demands with precise, sterile, ready-to-use tools that support faster recovery, reduce complications, and align with evolving patient care models like same-day discharge and ambulatory surgery. What challenges do single-use surgical instruments solve? They solve the pressing issues of cross-contamination, procedural inefficiency, and high sterilization costs. In underserved or rural healthcare facilities, limited access to reprocessing systems makes reusable tools a risk. Single-use surgical instruments eliminate these barriers, delivering hygienic, high-performance solutions that simplify workflows and improve patient safety. Where is adoption accelerating the fastest? Emerging markets such as India, Asia Pacific, Latin America, and sub-Saharan Africa are rapidly expanding healthcare infrastructure. With India conducting over 30 million surgeries annually, the demand for disposable, low-maintenance instruments are surging. These regions offer cost-effective pathways to scale sterile surgical care across both urban and rural settings. Request Sample Pages : Who are the key leaders—and how are they gaining ground? Market frontrunners include Ethicon, Medtronic, and BD, backed by global reach and deep R&D strength. Other major players like Smith+Nephew, STERIS, and B. Braun are expanding through acquisitions, strategic partnerships, and global training centers—including Smith+Nephew's surgical innovation center in Munich and STERIS's acquisition of BD's instrumentation business. What's the biggest challenge—and how do we overcome it? High cost and environmental sustainability are key hurdles. Smaller hospitals often rely on reusable tools due to budget limits. Simultaneously, increased medical waste is drawing scrutiny. Forward-thinking suppliers will win by delivering cost-efficient, eco-conscious single-use solutions backed by clear clinical and operational ROI. What should healthcare leaders be asking now?Not "Should we switch to disposables?"—but rather:• How can we cut infection risks without compromising efficiency?• Where can we reduce operational overhead from sterilization bottlenecks?• How do single-use instruments fit into our outpatient care strategy?• Which partners best align with our compliance, safety, and growth goals? Final Thought: In Sterility, There Is Strategy. In Simplicity, There Is global shift toward safe, efficient, and rapid-turnaround surgery is here. Single-use surgical instruments deliver the hygiene, performance, and reliability modern care demands. Facilities that embrace this model will lead on patient outcomes, cost control, and regulatory compliance. In the new era of surgery—precision, performance, and protection begin with single-use. For more information, Inquire Now! Related Reports: Surgical Sutures Market Wound Care Market Biosurgery Market Knee Replacement Surgery Market Surgical Suction Instruments Market Get access to the latest updates on Top Companies in Single-use Surgical Instruments and Single-use Surgical Instruments Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
First Lung Organoid with Organ-Specific Blood Vessels
Advanced lab-grown tissues help show how special lung cells develop, shedding light on rare ACDMPV disease and suggesting potential ways to repair damage from viral infections such as COVID-19 CINCINNATI, June 30, 2025 /PRNewswire/ -- A team of experts at Cincinnati Children's reports another powerful step forward in organoid medicine: success at making human lung tissue that can produce its own blood vessels. Their findings, published in the same month as a similar success involving liver organoids, reflect a new wave of advanced lab-grown tissues that can be used immediately in many research applications while moving ever closer to serving as living tissues that can directly repair damaged organs. Details were posted online June 30, 2025, in the journal Cell. "Prior to our study, the development of lung organoids with organotypic vasculature had not been achieved," says co-corresponding author Mingxia Gu, MD, PhD. "Notably, this method also could be applied to other organ systems such as intestine and colon." Gu, now at UCLA, was a member of the Center for Stem Cell and Organoid Medicine (CuSTOM) and Division of Pulmonary Biology at Cincinnati Children's while this research was conducted. Co-first and co-corresponding author Yifei Miao, PhD, (now at the Chinese Academy of Sciences, Beijing) also was with Cincinnati Children's for this work. Co-corresponding author Minzhe Guo, PhD, remains with Cincinnati Children's along with several co-authors involved in this study. Overcoming a major challenge Researchers have been working for years to grow organoids -- sometimes called "organs in a dish." Creating organoids involves converting mature human cells (such as blood or tissue cells) back into fetal-like stem cells that can be coaxed into growing a wide range of other tissue types. Unlike disconnected human cells kept alive in a dish, these are growing, developing mini-organs that form into seed-sized spheres that mimic the unique functions of full-sized organs. Intestines that absorb and secrete. Stomachs that produce digestive acids. Hearts that pulse. Brain tissues with firing nerve cells and so on. Cincinnati Children's has been a leader in organoid development since 2010 when experts here produced the world's first functional intestinal organoid grown from induced pluripotent stem cells (iPSCs). More recently, the challenge has been learning how to grow organoid tissues that can connect with the rest of the body to integrate nerve connections, blood vessels, bile ducts, immune systems and more. During pregnancy, these differing tissue types naturally find each other as the fetus matures and becomes more complex. Organoid developers seek to re-produce these steps in the laboratory, which eventually may allow people to receive custom-grown tissues that could patch damage or boost disrupted functions. Simpler forms of organoids have already begun transforming medical research, allowing many scientists to use living human tissue models to study disease while reducing current reliance on animal models to develop new medicines. But without the ability to make internal blood vessels, the tiny seeds lack the ability to grow into larger, more useful tissues. How the team solved the vascular riddle The new study thoroughly recounts the results of many experiments the team conducted to demonstrate success at inducing blood vessel formation. The work spanned four years and involved more than 20 people at Cincinnati Children's plus collaborations with experts at several other organizations. "The challenge in vascularizing endodermal organs, particularly the lung, stems from different signaling requirements for lung epithelial versus vascular differentiation," says Miao. "Our success in this endeavor is attributable to our unique differentiation method." In essence, the team grew iPSCs from multiple cell types then found the right moment to introduce them to each other. The resulting cell signals helped flip a developmental switch so that progenitor cells that could have become either blood vessels or the outer walls of the lung wound up becoming blood vessels. In achieving this vital step, the team: Produced lung organoids that include respiratory bronchial epithelial cells (RAS cells), a human cell type not previously reported in conventional lung organoid models. Pinned down the developmental moments when a rudimentary gut tube begins to send some cells to form the lungs while sending other cells to form the stomach and intestine. While the basic steps of this transformation have been studied in animals, it had not been possible to study this stage of development in humans without killing fetuses. Demonstrated that the rare disease ACDMPV occurs when cell signaling "crosstalk" gets disrupted during this early blood vessel formation stage. Within days of birth, infants born with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) struggle to breathe because their lungs' air sacs (alveoli) and blood vessels are malformed. Nearly all infants with this condition die within the first month of life, according to the National Organization for Rare Disorders. Revealed key functional information about the cells involved in gas exchange inside the human lung. Their learnings help explain the damage within tiny blood capillaries that occurs in the lungs in response to injuries. These new clues offer fresh ideas for developing ways to protect and potentially restore affected lung tissues. What's Next? Cincinnati Children's has filed patent applications related to the methods developed here to produce organoids with blood vessel formation capabilities and the CuSTOM team is moving to further develop this technology. "We look forward to continuing to learn more about the fundamental biology involved in organ formation and applying those discoveries to improving outcomes across a wide range of difficult human diseases and conditions," says Aaron Zorn, PhD, co-director of CuSTOM and director of the Division of Developmental Biology. In addition to publishing these findings in Cell, co-authors plan to present their work at the Keystone conference in Kyoto, Japan (iPSCs: Progress, Opportunities, and Challenges) in January 2026. About the study Cincinnati Children's co-equal first authors were Miao, Nicole Pek, BS, and Cheng Tan, MD. Contributing co-authors from Cincinnati Children's were Cheng Jiang, MS, Zhiyun Yu, PhD, Kentaro Iwasawa, MD, PhD, Min Shi, MD, PhD, Daniel Kechele, PhD, Nambirajan Sundaram, PhD, Victor Pastrana-Gomez, MSTP student, Debora Sinner, PhD, Cheng-Lun Na, PhD, Keishi Kishimoto, PhD, Jason Tchieu, PhD, Jeffrey Whitsett, MD, Kyle McCracken, MD, PhD, Michael Helmrath, MD, James Wells, PhD, Takanori Takebe, MD, PhD, and Aaron Zorn, PhD. Contributing co-authors included experts from Harvard Medical School, Icahn School of Medicine at Mount Sinai, Sophia Children's Hospital (The Netherlands), Boston University This research also was supported by the Discover Together Biobank, the Bio-Imaging and Analysis Facility, and the Integrated Pathology Research Core at Cincinnati Children's and the University of Cincinnati Proteomics Laboratory. Funding sources for this work included: the National Institutes of Health (R01HL166283, DK128799-01, N01-75N92020C00005 and R01HL095993); an Endowed Scholar Award from the Cincinnati Children's Research Foundation; the American Heart Association (1013861 and 906513); the Falk Transformational Awards Program; and the Brigham Research Institute. Learn more about working with CuSTOM Learn how donors can support ongoing organoid research at Cincinnati Children's View original content to download multimedia: SOURCE Cincinnati Children's Hospital Medical Center Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
5 days ago
- Associated Press
MiRus Siegel™ TAVR US Early Feasibility Study (EFS) 30 Day Results Presented at NY Valves Meeting
ATLANTA, July 2, 2025 /PRNewswire/ -- The MiRus Siegel™ Valve was featured in three podium presentations at the NY Valves meeting last week. Pradeep K. Yadav MD, Piedmont Heart Institute, Atlanta and Raj R. Makkar MD, Cedars Sinai Heart Institute, Los Angeles presented patient case studies and the 30 day results of US Early Feasibility Study (EFS). In the US EFS, 15 patients with severe, symptomatic aortic stenosis (AS) were treated at Piedmont, Cedars Sinai, Stanford, Mayo Clinic and Naples. At 30 days, there were no deaths, strokes or re-hospitalizations. No patients had vascular complications, PVL (> moderate) or required a permanent pacemaker. Core lab echocardiographic data demonstrated a mean gradient of 6.3 mmHg, and valve area of 2.8 cm2 . The Siegel valve represents several firsts in TAVR: 8 French delivery sheath allowing less invasive procedures and broader patient access, particularly for women; the only Nickel-free THV allowing treatment of the 20% of Americans suffering from Nickel allergies; precise delivery due to lack of foreshortening and intrinsic commissural alignment; dry porcine pericardial leaflets with anti-calcification treatment and with the valve pre-mounted on the balloon. 'This is the first TAVR to have no foreshortening during implantation and along with small vascular access, makes it very user friendly and should also lead to fewer pacemakers and vascular complications' commented Pradeep K. Yadav, MD. 'The lack of nickel is also very appealing – we were able to treat a patient with severe nickel and cobalt allergy.' The combination of low delivery system profile and excellent hemodynamics is made feasible by the unique properties of the Rhenium alloys pioneered by MiRus including high yield strength, fatigue resistance and minimal recoil. 'The gradients and valve areas with the Siegel valve are outstanding' stated Raj R. Makkar, MD. 'Valve placement is very precise and allows us to protect the conduction system – one of our patients was quite elderly with pre-existing conduction system injury and we were able to replace his valve without having to place a permanent pacemaker.' About MiRus, LLC. MiRus is a life sciences company headquartered in Marietta, Georgia that has developed and is commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of spine, orthopaedic and structural heart disease. Inspired by the pioneering material science of NASA for rocket engines, MiRus has created Rhenium based medical alloys that are transforming medicine by making surgeries less invasive and implants safer and more durable. Find out more information about MiRus at Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements. The Siegel TAVR system is an investigational device and not FDA approved. * MiRus® , Siegel™ are all trademarks of MiRus, LLC. Contact: Pam Cowart VP of Clinical Affairs [email protected] 770-861-4804 View original content to download multimedia: SOURCE MiRus
